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Background
Cancer immunotherapy has a long history in the clinic.
William Coley was an orthopedic surgeon in the late
1800’s who noted marked tumor regression in a patient
with severe erysipelas. Based on this observation, he
hypothesized that stimulating the immune system could
effectively treat cancer. Thus, over the next decades he
gave various bacterial products, including live bacteria,
to patients with advanced cancers [1]. Although toxicity
was often substantial, he and his colleagues noted tumor
regressions in some patients, particularly those with
bone and soft tissue sarcomas. His work was ground-
breaking in strategy and method, but eventually fell out
of favor due to lack of scientific control and the advent
of radiotherapy and chemotherapy for cancer treatment.
Despite this, he was a pioneering physician-scientist. His
work is notable because his hypothesis that the immune
system can be harnessed to treat cancer is the bedrock
of the striking success of cancer immunotherapy today.
In contrast to his relatively unsystematic approach,
drug development has historically followed a carefully
delineated pathway of sequential trials that systematic-
ally generate data characterizing the safety profile and
clinical activity of a therapeutic agent in increasing num-
bers of patients [2]. These trials begin with early Phase 1
studies in small numbers of patients that evaluate the
toxicities, pharmacokinetics (PK) and pharmacodynamics
(PD) of a novel agent, and define a dose and schedule for
further evaluation. Exploratory Phase 2 studies enroll
greater numbers of patients to further characterize the
side effect profile and estimate the anti-tumor activity of
the therapy, typically in a given tumor type. Randomized
Phase 3 clinical trials then enroll larger numbers of
patients with a specific type of cancer, comparing the new
therapy to placebo and/or the current standard of care to
confirm the safety and clinical activity of the new
intervention. This drug development system is designed
to support the marketing approval of more active and/or
less toxic cancer therapies for patients based on Phase 3
clinical trial data in large numbers of patients. Phase 4
post-marketing studies aim to generate additional safety
and clinical efficacy data for marketed products.
The need for rapid and efficient cancer drug development
has never been greater. The sequencing of cancer genomes
has identified multiple rearranged or mutated targets that
are druggable, ushering in the era of precision medicine.
Concomitantly, advances in our knowledge of the molecu-
lar and cellular basis of the antitumor immune response
has driven the development of multiple single-agent cancer
immunotherapies. These agents target nonmalignant im-
mune cells, and have often shown striking clinical activity
across multiple tumor histologies. Importantly, the activities
of targeted therapies and immunotherapies frequently
intersect, with molecularly targeted therapies often pro-
moting the antitumor immune response. Moreover, the
activity of both precision medicines targeting genomic
aberrations in tumor cells and immunotherapies targeting
the antitumor immune response is maximized by the de-
velopment of companion diagnostics that identify patients
most likely to benefit from them. This may require the
development of a companion diagnostic through a parallel
regulatory pathway, or may be done simultaneously in
registration clinical trials. Given the array of available
targets, drugs, and biomarkers of response and resistance
to therapy it is clear that traditional approaches to drug
development are unable to support the speed and level of
sophistication required for the development of effective
cancer therapies today.
New trial designs more effectively and efficiently tie
the biologic activity of new agents to clinical activity and
are more appropriate in today’s landscape than the trad-
itional phased approach based on associations between
toxicity and clinical activity [3]. Platform trials evaluate
multiple therapies in a given indication alone or in com-
bination, and may evolve over time to test new agents
and drop drugs with limited activity or excessive toxicity.
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Indication finding trials evaluate therapies across histolo-
gies or disease subtypes within a given histology to define
the most appropriate indications for further development.
Adaptive trials are conducted as unblinded trials that flex
to incoming data in real time based on prospectively de-
fined decision rules. Importantly, early first-in-human
Phase 1 clinical trials increasingly include expansion co-
horts designed to test hypotheses distinct from the histori-
cal objectives of traditional Phase 1 clinical studies [2, 4].
These cohorts may be designed to explore more sophisti-
cated PK and PD parameters, alternative drug dose and
schedule schemas, improved product formulation or ad-
ministration strategies, predictive biomarkers of thera-
peutic response and resistance, and assessment of clinical
activity. Most recently, these trials have begun to add large
expansion cohorts of 100 patients or more [2]. The total
sample size of these clinical trials may grow to exceed well
over 1000 patients. The addition of new expansion co-
horts to first-in-human trials to test emerging clinical hy-
potheses in real time can clearly expedite the development
of new cancer therapies, delivering better treatments to
patients much faster.
Strategies for meeting the challenges and mitigating
the possible risks of this strategy must be identified and
developed with the input from all stakeholders. This is
particularly true for combination cancer immunotherapies
that integrate immuno-oncology agents with standard che-
motherapy or radiation, molecularly targeted therapies, or
other immuno-oncology agents. These combination im-
munotherapy strategies are rapidly entering the clinic. Im-
portantly, they have the potential for therapeutic synergy,
but also a significant risk of enhanced and unexpected
toxicities. The optimal integration of modern translational,
clinical, and regulatory science is essential for delivering
new single agent and combination cancer immunother-
apies to patients as safely and efficiently as possible.
Case studies of cancer immunotherapy trials
The clinical success of immune checkpoint antagonists
targeting the PD-1 pathway in multiple tumor types pro-
vides clear evidence that harnessing the immune system
can lead to durable tumor regressions in cancer patients.
As a result, enthusiasm for cancer immunotherapy has
never been higher, and complex trials of single agent and
combination cancer immunotherapies are entering the
clinic at a dizzying pace. George Santayana once said,
“Those who fail to learn from history are doomed to re-
peat it.” This may be true for the prior failures and risks of
novel cancer immunotherapies. We also argue that those
who fail to learn from history will not develop better ways
of moving forward. We should apply lessons from our
successes to create the most effective pathway for develop-
ing cancer immunotherapies. Here we present several case
studies in cancer immunotherapy drug development to
highlight important lessons from the past. These lessons
illustrate innovative, rapid clinical development pathways
for novel immunotherapy agents with clinical benefit
highlight the need for appropriate cautions to detect and
manage potential adverse events early in the drug devel-
opment process.
Unique pathways to drug approval
The PD-1 antagonist pembrolizumab
The clinical development of pembrolizumab is an ex-
ample of a modern, seamless drug development strategy
that facilitates the rapid testing and approval of a novel,
highly promising agent under the umbrella of a single
clinical trial [2, 3]. The first-in-human study began in
2011 to define the recommended phase 2 dose for ad-
vanced solid tumors. A high level of clinical activity ob-
served in the patients initially enrolled led to an increase
in the sample size for patients with melanoma in order
to evaluate dose characteristics, overall response rates,
and disease control rates for this disease. Similarly, sig-
nificant clinical activity in non-small cell lung cancer
(NSCLC) prompted the addition of a cohort of patients
with NSCLC to estimate the overall response rate in this
second disease indication. Additional cohorts of patients
with other types of cancer were added, and ultimately
over 1200 patients were treated on this open-label Phase
1b trial [5]. One cohort enrolled 173 patients with unre-
sectable or metastatic melanoma previously treated with
ipilimumab or BRAF/MEK inhibitors as appropriate,
randomizing them to 2 mg/kg or 10 mg/kg of pembroli-
zumab every 3 weeks [6]. Initially patients were random-
ized at a 2:1 ratio, and then the protocol was adjusted to
achieve a 1:1 randomization. The primary endpoint for
these cohorts was the overall response rate by RECIST.
Peak and trough blood samples were obtained for phar-
macokinetic analysis. The overall response rate and safety
profiles were similar for both doses tested, though the
peak drug exposure was higher for the 10 mg/kg dose co-
hort. The clinical efficacy observed in this cohort was suf-
ficient to support accelerated approval of pembrolizumab
at 2 mg/kg every 3 weeks for unresectable or metastatic
melanoma in September 2014, only 3 years after the trial
began. Subsequently data from the NSCLC cohort [7] led
to accelerated approval of pembrolizumab for metastatic
PD-L1+ NSCLC with a companion diagnostic, the PD-L1
IHC 22C3 pharmDx test, in October 2015. This unusually
rapid path to marketing approval for pembrolizumab in
two disease indications was possible due to the striking
clinical responses observed and the durability of clinical
benefit, and included breakthrough therapy designation, the
thoughtful use of expansion cohorts, the development of a
companion diagnostic assay for at least one tumor type,
and an accelerated approval strategy developed in close
communication with the FDA.
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The PD-1 antagonist nivolumab
Similar to pembrolizumab, the clinical development path
of nivolumab, another PD-1 inhibitor, was also shortened.
Ultimately, accelerated approval in unresectable or advanced
melanoma was granted in December 2014 based on clinical
efficacy data derived from a subset of 120 patients enrolled
on a randomized Phase 3 clinical trial that screened 631 pa-
tients at 90 sites across the world [3].
The oncolytic virus talimogene laherparepvec (T-VEC)
T-VEC, a genetically-modified oncolytic herpesvirus en-
coding granulocyte-macrophage colony-stimulating fac-
tor (GM-CSF), is the first oncolytic virus to demonstrate
clinical benefit in a prospective, randomized phase III
clinical trial [8]. T-VEC has a novel mechanism of action
that includes both the direct lysis of tumor cells and the
induction of systemic host anti-tumor immunity [9]. The
clinical development of T-VEC in metastatic melanoma
required considerable thought to define the eligible pa-
tient population, which required accessible tumor for
direct injection of virus, attention to pre-existing herpes
virus serology, and the measurement of viral shedding to
detect household transmission. The pivotal phase III
trial also required a control arm and a clinical endpoint
appropriate to a novel class of immunotherapy agent, as
earlier phase studies of T-VEC had demonstrated disease
progression before regression in some patients [10]. In
the phase III trial, 436 patients were enrolled using a
2:1 randomization to T-VEC or recombinant GM-CSF
(selected as the control in this study). In this trial the
2:1 randomization was utilized for efficiency of clinical
development in a compromise between the use of his-
torical controls and randomized concurrent controls,
where the concurrent randomized controls help to con-
firm that historical controls are an appropriate compari-
son group and the level of imbalance in the randomization
reflects the level of confidence in historical control data
[11]. The trial was completed within a 2-year period.
Patients were required to have accessible but unresectable
melanoma, and were allowed to continue treatment des-
pite clinically insignificant disease progression. The pri-
mary endpoint was durable response rate, defined as an
objective complete or partial response by modified WHO
criteria beginning within 12 months of starting study
treatment and lasting at least 6 months from the time of
onset. This trial demonstrated a significant improvement
in durable response rate, with improvements in objective
response rate, progression-free survival and quality of life.
Subset analyses revealed an especially strong effect on re-
sponse rate and overall survival for patients with stage III
or IVM1a disease [7]. Based on the durable response rate
and quality of life improvements (psychological distress)
associated with regression of cutaneous and soft tissue
disease, the FDA approved T-VEC for patients with
advanced melanoma in October 2015. The drug was
also approved by the European Medicines Agency in
December 2015 for the treatment of patients with ad-
vanced stage III and IVM1a melanoma only, based on
the subset analyses. This trial illustrates the use of a
novel clinical endpoint that incorporates both response
and duration elements to capture the known delayed
kinetics of clinical responses often observed with im-
munotherapy agents.
Unique toxicities and complications
The CD28 superagonist TGN1412
The clinical application of agents that target regulatory
molecules within the immunologic synapse began well
before the current era of immune checkpoint modula-
tion targeting the CTLA-4 and PD-1 pathways (among
others). TeGenero developed a first-in-class humanized
superagonist monoclonal antibody specific for CD28,
TGN1412 [12, 13]. CD28 is a cell surface receptor that
engages with its ligands CD80 and CD86 on professional
antigen presenting cells to stimulate T cell responses
during antigen recognition. TGN1412 induces very
strong CD28 signaling that requires only tonic antigen-
specific T cell receptor (TCR) signaling. Thus, the major-
ity of the signal for T cell activation is delivered through
CD28 rather than through the TCR. TGN1412 entered
the clinic on March 13, 2006, when six healthy volun-
teers received an intravenous injection of the CD28
superagonist at about the same time. They all developed
a life-threatening cytokine-release syndrome (CRS), and
were admitted to the intensive care unit within 12–16 h
after dosing; all six survived. This unexpected and life-
threatening toxicity immediately led all involved to ask
why preclinical data did not predict this life-threatening
toxicity, and it took 6 years to dissect the science.
In preclinical models, CD28 superagonists result in poly-
clonal T cell activation that is rapidly counter-regulated by
the expansion and activation of regulatory T cells (Treg) to
prevent over-exuberant immune activation. Several pe-
culiarities of the preclinical data lend insight into what
happened. First, in the healthy volunteers, tissue-resident
CD4+ effector memory T cells (TEM) were the source of
cytokines (IL-2, TNFα, and IFN-γ) resulting in CRS. Be-
cause the accumulation of TEM is driven by repeated ex-
posure to infectious agents, it does not occur in rodents
housed in clean rooms. Thus, the relative TEM/Treg ratio
in laboratory rodents and in humans differs, and favors
immune hyperstimulation in patients. Moreover, low dose
superagonist CD28 only expands Tregs, whereas doses at
the level used in the trial expands both TEM and Tregs.
Thus, the dose selected for study compounded the risks
associated with the biological difference between rodents
and humans. Second, TGN1412 had been given to cyno-
molgus macaques at 500-fold higher doses than to the
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human volunteers without adverse effect. Human and ma-
caque CD28 has the same sequence and binds TGN1412
with the same affinity. However, macaque CD4+ T cells,
but not human CD4+ T cells, lose CD28 expression as
they differentiate into TEM cells. This difference was over-
looked during primate testing. Finally, treating human
peripheral blood mononuclear cells with TGN1412 did
not induce cytokine release or proliferation. Subsequent
investigations showed that when PBMC were “pre-condi-
tioned” at high density to facilitate cell-cell contact mim-
icking tissue residence, the sub-threshold, tonic level of T
cell activation required for the activity of TGN1412 that T
cells lose during trafficking through the circulation was re-
stored. Pre-culturing PBMC under high density conditions
suggests that if TGN1412 had been given at the minimum
anticipated biological effect level (MABEL), the first dose
for the trial would have been 200-fold lower. This trial
taught us that “the absence of evidence” is not the same as
“evidence of absence” for drug-related toxicity [13], argu-
ing that receptor occupancy assays and in vitro surrogate
response markers—dosing based on the minimum bio-
logic effect level (MABEL)—may be superior to the no ob-
served adverse effect level (NOAEL)-based dosing used in
this trial.
CAR-T cell therapy
Chimeric antigen receptor T (CAR-T) cell therapy is a
highly active cancer immunotherapy that yields dramatic
tumor regressions. CAR-T cells are T cells engineered to
express an artificial antigen receptor derived from the vari-
able region of an antigen-specific antibody and linked to
signaling components of the T cell receptor and co-
stimulatory molecules for T cell activation. Like TGN1412,
CAR-T cell therapy can result in massive T cell expansion
in vivo, leading to CRS [14, 15]. CAR-T cell therapy is also
associated with macrophage activation syndrome (MAS)
or hemophagocytic lymphohistiocytosis (HLH), and a pre-
viously unrecognized form of focal neurologic toxicity.
These are not antigen-specific toxicities, but are associated
with high circulating levels of several cytokines, including
interleukin-6 and interferon-γ. Interleukin-6 has emerged
as the central mediator of severe CRS-associated toxicity,
and therapy for CRS includes tocilizumab and cortico-
steroids along with aggressive supportive care. Despite
knowledge of the pathophysiology of this syndrome, its
management remains a challenge. In 2014, clinical trials
of CAR-T cells were temporarily put on hold at Memorial
Sloan Kettering Cancer Center due to several infusion-
related patient deaths, prompting modifications to the
protocol [16]. This included reducing the dose of CAR-T
cells in patients with large tumor burdens, as the degree
of tumor load appeared to correlate with the severity of
CRS. The protocol was also modified to exclude patients
with a history of cardiac problems, and decreased the time
period between the end of induction chemotherapy and
the start of CAR-T cell therapy by 50%. It also prompted
the development of a consensus statement for the man-
agement of CRS from leaders in the field [17]. In addition
to CRS and associated syndromes, T cell therapy may
be associated with other unexpected toxicities [18]. An
affinity-enhanced TCR for MAGE-3 under develop-
ment for melanoma and myeloma caused cardiogenic
shock and death in the first two patients who received
it due to cross-reactivity to an unrelated peptide, titin,
on striated muscle [19].
The listeria-based vaccine axalimogene filolisbac
A Listeria monocytogenes-based bacterial vaccine target-
ing human papilloma virus (HPV) has been tested in pa-
tients. In one clinical trial, a patient with cervical cancer
was treated on study, with the last dose given in early
2013. In July 2015 the patient was hospitalized, and tests
discovered the engineered Listeria bacteria in her blood-
stream. The patient died in August 2015. The death was
attributed to disease progression, but the FDA put four
clinical trials testing axalimogene filolisbac on clinical
hold in October 2015. The presence of axalimogene filo-
lisbac in the bloodstream of this patient was ultimately
attributed to colonization of the biofilm overlying an
implanted medical device, seeding the device for re-
emergence of the agent at a later date. Based on evaluation
of the event, the protocol inclusion/exclusion criteria were
modified to exclude patients with indwelling medical de-
vices that are a high risk for biofilm colonization and can-
not be easily removed. Study procedures were modified to
require the strict use of a dedicated indwelling line for ad-
ministration of the agent, a 6-month course of antibiotics
after the last dose of axalimogene filolsibac was imple-
mented, and additional patient surveillance and longer
term monitoring measures were put in place. The clinical
hold was lifted in December 2015.
Challenges and opportunities
The accelerated approvals described above illustrate how
the timeline of drug development can be compressed
using innovative adaptive clinical trial designs that enroll
large numbers of patients in early trials coupled effectively
with ongoing consultation with regulatory authorities. In
large part due to these triumphs of drug development,
there are now dozens of clinical trials testing novel im-
munotherapies alone and in combination with other ther-
apies for the first time. This may include the first in
human testing of two novel immunotherapy agents with
the aim of testing them in combination under the um-
brella of a single protocol. The trials often grow to include
sites that span the globe with investigators who may have
relatively limited experience in cancer immunotherapy.
The vignettes above also highlight the importance of early
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detection of potential safety issues, the need to implement
effective communication strategies amongst the study
team, and the importance of efficiently implementing ad-
verse event management guidelines into clinical trials as
new data is accumulated. The progress we have made and
the number of immunotherapy agents entering the pipe-
line thus poses challenges in how to prioritize them, study
them most safely and effectively, and develop the most ra-
tional immunotherapy combinations for clinical testing.
Here, we discuss these challenges and propose some
strategies for meeting them.
Clinical endpoints
Advances in tumor immunotherapy have been dramatic
over the last five years. We now understand that the
kinetics of immune-mediated anti-tumor activity may be
delayed compared to that of cytotoxic chemotherapy or
targeted therapy. Immunotherapy mediates tumor regres-
sion indirectly through activation of immune responses
and/or inhibition of suppressive immune elements. This
may result in delayed tumor regression, with some pa-
tients even experiencing the progression of existing dis-
ease or the appearance of new lesions prior to eventual
disease regression. Furthermore, many immunotherapy
agents do not impact progression-free survival, but are as-
sociated with significant improvements in overall survival
[20]. Standard metrics for tumor response assessment
thus may not capture the true clinical benefit of cancer
immunotherapies, and the selection of clinical endpoints
may require re-thinking when immunotherapy agents are
being used as part of a cancer treatment regimen.
The use of alternative clinical endpoints for immuno-
therapy has already been widely discussed. First, the
atypical response patterns of cancer immunotherapy led
to the development of the immune-related response cri-
teria (irRECIST), which captures disease in bidimensional
measurements and allows for continued treatment in the
face of clinically insignificant disease progression [21].
Immune-related RECIST (irRECIST) was subsequently
simplified to modified RECIST criteria (mRECIST) cap-
ture disease in unidimensional measurements while still
allowing for the unique response patterns of cancer im-
munotherapies with apparent disease progression by
standard criteria that is clinically insignificant (delayed
response and/or pseudoprogression) [22]. A recent re-
port from the pembrolizumab Phase 1b study demon-
strated a significant rate of atypical responses, where
standard RECIST criteria appeared to underestimate
the benefit of pembrolizumab in about 15% of patients
[23]. Thus, accounting for the atypical response patterns
of cancer immunotherapy might prevent the cessation of
treatment in patients who will go on to benefit from can-
cer immunotherapy. Second, the durable response rate is
a novel clinical endpoint already successfully incorporated
into the registration strategy for T-VEC. It captures re-
sponse rates over a pre-specified time frame based on an-
ticipated time to disease progression, which may differ
across various cancer types. Importantly, the strong asso-
ciation between stable disease and improved overall sur-
vival increasingly reported for cancer immunotherapy
further supports disease control rate as a highly clinically
relevant endpoint. Disease control rate may be a particu-
larly appropriate endpoint in early studies of novel single
agent and combination cancer immunotherapies [24]. A
caveat to the use of disease control rate as an endpoint for
clinical trials is that it may be confounded by indolent dis-
ease biology: in the absence of a randomized control arm,
it could overestimate clinical benefit. One way to mitigate
this risk is the use of an imbalanced randomization such
as that used in the pivotal trial leading to the approval of
T-VEC. Third, the unusually high rate of complete re-
sponses seen in some recent combination immunotherapy
trials suggests that complete response could emerge as an
appropriate clinical endpoint for selected cancer immuno-
therapy strategies [25]. Finally, composite endpoints that
capture both the depth and duration of response may
be most appropriate for some cancer immunotherapies.
Efforts to develop novel endpoints appropriate to the
mechanism of action of the particular immunotherapy
strategy being tested are ongoing.
Patient selection/eligibility
The selection of patients for cancer immunotherapy tri-
als is key to their success. Four considerations are rele-
vant to cancer immunotherapy trials today. First, in the
past most trials enrolled patients who were immunother-
apy naïve. As these trials became more widespread, newer
trials started to exclude patients who had received prior
cancer immunotherapies. Given the growth of the field
and recent marketing approvals, this is likely no longer
feasible as a matter of course, and patients previously
treated with one agent may respond to re-challenge with
the same agent, or to another drug. Thus, the exclusion of
patients who have received prior immunotherapy should
be based on a strong scientific rationale, or immunother-
apy naïve and experienced patients could be studied in
separate study cohorts. Second, after initial reports that
PD-L1 expression within the tumor microenvironment
had potential as a predictive biomarker, many sponsors
defined eligibility for trials of PD-1 or PD-L1 antagonists
based on expression of PD-L1 within the tumor using a
pre-defined assay. Selection for intratumoral PD-L1 ex-
pression does appear to enrich for responses, and likely
helped to ferret out clinical signals in early studies. How-
ever, PD-L1 expression is not a perfect predictive bio-
marker. Four Phase 3 clinical trials in melanoma, NSCLC,
and RCC have evaluated PD-L1 expression as a predictive
biomarker of response to therapy with PD-1 pathway
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antagonists [25–28]. In these trials, higher PD-L1 expres-
sion is associated with more clinical responses and longer
survival, but significant numbers of PD-L1 negative pa-
tients also benefit from blockade of PD-1 signaling. Thus,
a significant challenge to the use of PD-L1 expression as a
predictive biomarker of response is that it is not a binary
variable. The level of PD-L1 expression for a given patient
may be more prognostic than predictive, with higher levels
associated with better clinical outcomes. Assay differences,
expression of PD-L1 by both tumor cells and infiltrating
immune cells, geographic variability of PD-L1 expression
within the tumor microenvironment, cellular localization
of PD-L1 (membranous versus cytoplasmic), and the dy-
namic nature of the immune response lend further com-
plexity to the development of immunologic biomarkers
that reliably predict response to immunotherapy. It is
likely that a composite signature may be most informative.
Finally, the relationship between PD-L1 expression and
clinical benefit is likely to vary with tumor type. PD-L1
did not predict clinical benefit with nivolumab in renal cell
carcinoma [28], but did in melanoma and selected subtypes
of lung cancer but not others [25–27]. Third, incorporating
high quality biomarker programs designed to identify pre-
dictive biomarkers of primary or secondary resistance into
these trials can help to prioritize the most rational im-
munotherapy combinations for clinical development [29].
Fourth, given the high level of excitement about immune
checkpoint blockade, patients increasingly are asking to be
treated off-label with approved agents, or under a single pa-
tient IND for investigational agents. Many of these patients
may present with PD-L1 testing results on their tumor
done as part of a trial, using one of the two diagnostic tests
that have now been approved by the FDA, or even another
assay. The lack of standardization for PD-L1 testing and
the dynamic nature of PD-L1 expression may create sub-
stantial uncertainty in determining the relevance of the re-
sult at a given point in time for a particular patient. Given
both the opportunities at hand and data that support a
higher quality of care for patients on trial, clinical trial par-
ticipation should be strongly encouraged for potentially eli-
gible patients to ensure the field continues to move forward
at a rapid pace and we bring the best drugs to the most
appropriate patients.
Trial modifications
The rapid growth and sheer size of these trials present
challenges to communication, ensuring that investiga-
tors, sponsors, contract research organizations, investi-
gational review boards and regulatory authorities remain
up-to-date on the current data and modifications to the
protocol, that patients are fully informed, and that pa-
tient safety and data quality are maximized. As trials are
modified, the rationale, supporting data, and hypotheses
to be tested in the amendment must be clearly defined.
This could include evaluating additional tumor types for
signals of clinical activity, modified drug doses or schedules,
and/or predictive biomarkers of response or resistance
(among other questions). The sample size justification and
statistical analysis plan should be described, and early stop-
ping rules for futility and/or toxicity clearly defined. Study
participants should be kept informed of new developments
in the study that warrant major changes to the study design
through updated informed consent documents. Scientific
review committees, institutional review boards, and the ap-
propriate regulatory authorities should be notified of major
changes to the study design and sample size/patient cohorts
being evaluated. A plan for patient follow up should also be
clearly delineated to collect late safety and efficacy signals.
Trial communications
In cancer immunotherapy trials, unexpected (and ex-
pected) toxicities can quickly emerge, requiring an in-
formed, early, and nimble response from the investigator
for maximal patient safety. These events may also provide
a limited window for evaluating patient samples that can
elucidate the pathophysiology of an unexpected or rare
event. Effective real-time communication between the
study investigators and the sponsor will facilitate dissecting
the science in the patient to inform the development of the
most effective therapy for a specific adverse event (such as
the use of tocilizumab for CRS). Additionally, the atypical
clinical response patterns that may be associated with
cancer immunotherapy can be tricky to manage for in-
vestigators, and difficult for patients to understand. For
investigators with less experience in immunotherapy,
having defined management algorithms and an infra-
structure to fall back on to guide both toxicity manage-
ment and the management of atypical clinical responses is
critical. A defined communications strategy for cascading
information about important adverse events (expected or
unexpected) as well as atypical response patterns should
be implemented early in the study. Regularly scheduled
“state of the study” calls have proven very useful to make
sure all stakeholders are optimally informed. The commu-
nications between the sponsor and investigators across
multiple sites that occur on these calls are highly valuable.
Monthly trial newsletters and toxicity management
hotlines are other strategies that have been used to in-
form and support study investigators faced with serious
immune-related toxicities new to them.
Trial oversight
An excellent, well-defined communications plan including
all trial stakeholders is the first step to rigorous trial over-
sight. A steering committee that includes study investiga-
tors should also be considered to provide critical advice
and insights from individuals with expertise in the
field and “on-the-ground” experience with the study,
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particularly for new agents or novel immunotherapy
combinations. Once a study incorporates advanced de-
sign features (randomization, for example) and/or ma-
tures sufficiently that it could support a registration
for marketing approval, it may be appropriate to con-
sider an oversight committee that includes external ex-
perts with subject matter expertise who are not directly
involved in the study. These individuals can provide an
objective voice in monitoring the data and the evolution
of the study design to ensure that the safety and clinical
activity signals seen are considered appropriately across all
disease cohorts, and the clinical science is maintained at
the highest level of quality. These strategies are similar to
historic data safety monitoring boards but demand more
frequent updates and interaction among all stakeholders.
Conclusions
Recent advances in cancer immunotherapy clearly illus-
trate virtually unprecedented long-term clinical benefit in
some advanced cancer patients, and the potential for cure
seems tangible. In lock step with transforming patient
care, we have also already begun to revolutionize the drug
development enterprise. Given the sheer number of in-
vestigational agents and potential combination cancer
immunotherapies before us, the opportunity to make a
major impact on the world’s cancer burden and on pa-
tient’s lives has never been greater. This is an exciting
time in the field, and it is critical to expedite the devel-
opment of new cancer immunotherapies. It is also im-
perative to remain vigilant in order to detect safety
signals early, and incorporate adverse event manage-
ment procedures rapidly to prevent avoidable toxicity.
We should continue to re-structure and adapt the sys-
tem to fit the opportunities before us, working as a
team across the drug development enterprise to safely
deliver transformative cancer immunotherapies to the
patients and families that need them. We should learn
from past experiences and recent successes, and com-
municate emerging clinical trial data often and clearly
among investigators, local review boards and federal
regulators. These strategies will help to ensure that we
maintain the highest level of ethical and scientific rigor
as the clinical development of cancer immunotherapy
evolves and we continue to innovate to eradicate cancer.
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